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Abstract Whole blood gene expression profiling has the
potential to be informative about dynamic changes in dis-
ease states and to provide information on underlying
disease mechanisms. Having demonstrated proof of con-
cept in animal models, a number of studies have now tried
to tackle the complexity of cardiovascular disease in
human hosts to develop better diagnostic and prognostic
indicators. These studies show that genomic signatures are
capable of classifying patients with cardiovascular diseases
into finer categories based on the molecular architecture of
a patient’s disease and more accurately predict the likeli-
hood of a cardiovascular event than current techniques. To
highlight the spectrum of potential applications of whole
blood gene expression profiling approach in cardiovascular
science, we have chosen to review the findings in a number
of complex cardiovascular diseases such as atherosclerosis,
hypertension and myocardial infarction as well as throm-
boembolism, aortic aneurysm, and heart transplant.
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Introduction
Despite significant advances in our understanding of the
molecular mechanisms of cardiovascular disease, diag-
nostic tests for judging its severity and response to
therapeutic interventions remain invasive (angiography,
intravascular ultrasound) or suffer from lack of precision.
The need for improved diagnostic tools for assessment, risk
stratification, therapy selection, and monitoring has
become all the more urgent in the context of an aging
population that is living longer and with increasing risk
factors of cardiovascular disease.
In contrast to DNA based testing that generally provides
information on disease predisposition and susceptibility,
dynamic genomic markers from disease tissues may pro-
vide insights into mechanism based processes associated
with disease states as well as biomarkers that can be used
for diagnosis, prognosis, drug response, and monitoring of
disease activity. Cardiovascular diseases, unlike other
disease entities where the primary disease tissues can be
obtained for diagnostic or prognostic analyses, do not
readily lend themselves to tissue collection. With increas-
ing feasibility and reliability in genomic technologies to
probe for disease and an awareness of the practical limi-
tations of collecting primary cardiovascular disease tissue
specimens, the need for reliable blood based biomarkers
that can report on disease states has grown tremendously.
Not only is blood easier to obtain compared to a tissue
biopsy, but it also contains a number of circulating cell
types such as platelets, neutrophils, peripheral blood
lymphocytes, and circulating stem cells that are mecha-
nistically associated with both myocardial and vascular
disease processes. Thus capturing the global genomic
response through changes in RNA expression in blood may
provide a useful tool for developing diagnostic and
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prognostic indicators for complex diseases, particularly
ones involving the vasculature or its circulating
components.
Instead of analyzing single genes, global gene expres-
sion provides a ‘‘molecular signature’’ that may distinguish
between one disease state and another. In addition to
identifying signatures or patterns of gene expression that
represent a disease state, analyses can be constructed to
identify representative pathway genes that might point to
novel pathophysiology relevant to the underlying disease
state. Peripheral blood gene expression signatures have
now been reported in a variety of conditions including
rheumatoid arthritis (Lequerre´ et al. 2006; Shou et al.
2006), systemic lupus erythematosis (Rus et al. 2004),
multiple sclerosis (Bomprezzi et al. 2003; Singh et al.
2007), asthma (Brutsche et al. 2002), solid malignancies
(Alizadeh et al. 2000; Golub et al. 1999; Valk et al. 2004),
solid organ transplantation (Baron et al. 2007; Horwitz
et al. 2004), as well as environmental exposures (Lodovici
et al. 2007; Wu et al. 2003; Dressman et al. 2007) (see
Table 1). Many of these conditions have an inflammatory
component and thus affect immune cells in the vascular
compartment. It is hypothesized that these cellular changes
are the basis for the differences in gene expression that is
observed in RNA extracted from whole blood specimens or
from specific circulating cell types.
The important role of inflammation in a number of
cardiovascular conditions like atherosclerosis (Libby
2002), essential hypertension (Yasunari et al. 2002), and
post-myocardial infarction (MI) remodeling (Frangogian-
nis et al. 2002), has been well established. This relationship
makes the study of peripheral blood leukocyte or whole
blood gene expression particularly well suited for devel-
oping more refined diagnostic and prognostic tests in
cardiovascular medicine (see Table 2) as circulating cells
‘sense’ the pro-inflammatory state. The greatest potential
of this approach would be the enhancement in accurately
classifying patients by the type and severity of their disease
and to individualize the therapy based on the biology of the
disease in an individual patient. This review broadly looks
at studies that used peripheral blood gene expression pro-
filing to develop a non-invasive tool for assessing vascular
disease burden or to provide a patient-specific risk profile
for patients with atherosclerosis risk factors, myocardial
Table 1 Peripheral blood gene expression profiling in a variety of conditions
Target cell Results References
Autoimmune Whole blood RNA 41 gene signature differentiated Infliximab responders from non-
responders.
(Lequerre´ et al. 2006)
Whole blood RNA 28 gene signature differentiated between blood samples from arthritic
and non-arthritic rats.
(Shou et al. 2006)
Whole blood RNA 29 gene signature best differentiated active versus inactive SLE (Rus et al. 2004)
Inflammatory Peripheral monocytes A 53 gene signature distinguishes between patients with active multiple
sclerosis and healthy controls.
(Bomprezzi et al. 2003)
Peripheral monocytes A 136 gene signature distinguishes active MS patients on TNF-alpha
therapy from treatment naı¨ve patients.
(Singh et al. 2007)
Whole Blood RNA 10 genes based composite score for diagnosing atopy and asthma
performed better than total IgE count with sensitivity and specificity
of 96% and 92%, respectively.
(Brutsche et al. 2002)
Neoplasm CD27+ and CD19+ B cells;
CD4+ T cells
2,984 gene signature could distinguish subtypes of diffuse large B cell
lymphoma.
(Alizadeh et al. 2000)
Bone marrow mononuclear
cell RNA
From 6817 genes tested, 50 found to be most highly correlated with
AML-ALL distinction and used to develop the classification scheme.
(Golub et al. 1999)
CD34+ blast cells RNA A set of 2856 genes allowed classification of AML into 16 distinct
groups.
(Valk et al. 2004)
Transplant CD4+ and CD8+ T-cell RNA 17 gene signature identified donor samples likely to cause GVHD with
80% accuracy.
(Baron et al. 2007)
Whole Blood RNA From 22, 125 gene profiled, 91 genes were differentially expressed
between rejection (grade 3A) versus controls (grade 0).
(Horwitz et al. 2004)
Environmental
exposure
Whole blood RNA 216 gene profile differentiated oxidative damage from active oxidative
damage in active and passive smokers
(Lodovici et al. 2007)
Whole blood RNA 62 gene profile correlated with severity of arsenic poisoning. (Wu et al. 2003)
Whole blood RNAa 25 gene signature differentiated between irradiated and non-irradiated
human blood with overall accuracy of 90%
(Dressman et al. 2007)
a Used gradient centrifugation to separate leukocyte fraction
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infarction, structural heart disease, transplantation, and
pulmonary hypertension. This field is in its infancy, but it
will contribute a series of novel tools for the practice of
genomic cardiovascular medicine.
Hyperlipidemia
Hyperlipidemia is a known risk factor for atherosclerosis
and developing a genomic signature of hyperlipidemia is
an important step in improving the assessment of disease
burden from atherosclerosis. Given the important role of
inflammatory cells (i.e. PBMCs) in atherosclerosis, Ma
et al. investigated the effect of lipids on the gene
expression profile of PBMCs. The researchers found that
PBMC gene expression profile varied with serum lipid
levels (Ma et al. 2007). Analyzing mRNA from 32 heal-
thy subjects, researchers found that 895 genes correlated
with LDL levels (480 negatively; 415 positively) and 687
genes showed correlation with HDL (434 negatively; 253
positively). Many of the identified genes mapped to a
previously known QTL that is associated with regulating
plasma lipid levels. Functional categorization of these
genes revealed that inflammatory genes were positively
correlated with LDL, triglyceride, and total cholesterol
levels, but negatively correlated with HDL. Moreover,
genes involved with fatty acid metabolism and electron
transport chain showed positive correlation with low-
density lipoprotein (LDL) levels and negative correlation
with high-density lipoprotein (HDL) levels. Finally,
platelet activation genes (PF4 and PPBP), which the team
had earlier shown up regulated with CAD (Ma and Liew
2003), demonstrated inverse correlation with HDL levels.
Although the diagnostic or predictive accuracy of this
approach was not determined in this investigation, this
work does provide a framework for doing so in future
investigations. Other work in this area has shown that
blood genomic profile can also serve to distinguish
between familial and non-familial hyperlipidemia. Work-
ing with immortalized monocyte cell lines from
individuals with familial combined hyperlipidemia
(FCHL), Morello et al. showed that 166 genes were dif-
ferentially expressed between FCHL derived cells and
normal control cells. The 166 gene profile was tested in
an independent cohort of control subjects that were not
matched for age, BMI, or FCHL status, but had similar
lipid levels (Morello et al. 2004). The transcriptional
analysis not only separated groups of FCHL and control
cells, but also showed further sub-categorization of FCHL
cell lines. That peripheral gene expression signatures can
be defined for hyperlipidemia suggests that it should be
possible to develop similar profiles for more complex
vascular disease phenotypes such as atherosclerosis or
plaque vulnerability.
Table 2 Peripheral blood gene expression profiling in cardiovascular diseases
Indication Target cell Results Ref
Dyslipidemia Whole blood RNA 895 genes correlated with LDL, 687 with HDL, and 364 with total
cholesterol. 188 genes correlated both with LDL and total cholesterol.
(Ma et al. 2007)
Essential
hypertension
Whole blood RNA 680 genes were found differentially expressed in untreated hypertensives
compared to normotensive controls. On the other hand only 7 genes were
differentially expressed in treated normotensives compared to
normotensive controls.
(Chon et al. 2004)
Type 2 Diabetes Whole blood RNAa Among the various pathways analyzed, 48 genes of JNK correlated with
diabetes and glycemic control while 92 genes of OXPHOS correlated only
with diabetes status irrespective of glycemic control.
(Takamura et al. 2007)
Myocardial
infarction
Platelet RNA From [18,000 probe sets, 54 probe sets showed differential expression
between STEMI and stable CAD. Moreover, MRP8/14 predicts risk of
future cardiovascular event.
(Healy et al. 2006)
Aortic Aneurysm Whole blood RNA A 41 gene signature identified between patients with aortic aneurysm and
controls with 78% accuracy along with a sensitivity and specificity of 72%
and 90% respectively.




Whole blood RNA From 24, 650 genes profiled, 106 gene signature identified (1) patients with
APS vs non-APS patients with VTE. (2) Predicticted likelihood of APS in
patients with VTE. (3) Predicted likelihood of VTE in patients with aPLAs
but not APS.
(Potti et al. 2006)
Cardiac
transplant
Whole blood RNA From 252 genes profiled, an 11 gene test discriminated between moderate/
severe rejection and quiescence.
(Deng et al. 2006)
Pulmonary
hypertension
Whole blood RNAa A 106 gene signature identified with 95–100% accuracy patient with
pulmonary hypertension versus controls.
(Bull et al. 2004)
a Used gradient centrifugation to separate leukocyte fraction
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Hypertension
Evidence accumulated over the past five decades has estab-
lished indisputable relationship between hypertension and
risk of cardiovascular disease, which includes many seque-
lae of atherosclerosis like ischemic heart disease and stroke
(Chobanian et al. 2003). Results from the Framingham study
have shown that risk of cardiovascular disease (CVD) dou-
bles in even pre-hypertensives (130–39/85–89) compared to
normotensives (\120/80) (Chobanian et al. 2003). Antihy-
pertensive therapy can reduce but not completely normalize
the risk of developing atherosclerosis. Current modalities,
however, do not allow identification of such individuals who
are at risk despite normalization of blood pressure. To begin
tackling this problem, Chon et al looked at the responsive-
ness of gene expression profiling of PBMCs to
antihypertensive medications (ACE inhibitor and beta
blocker). Not surprisingly, untreated hypertensives showed
upregulation of oxidative stress and inflammatory genes
while suppression of antioxidant genes. However, the
expression of such genes returned to baseline once the
patients were controlled to\140/85 with pharmacotherapy
(Chon et al. 2004). Using six uncontrolled hypertensives
([140/85) and six pharmacologically managed hyperten-
sives (\140/85), gene expression patterns of hypertensives
revealed 680 genes that were upregulated as compared to
patients who were normotensive on medication. The overall
pattern of gene expression in untreated hypertensives
showed upregulation of proinflammatory interleukins and
cytokines and down regulation of anti-inflammatory inter-
leukin receptors. Moreover, upregulation of the serotonin 2b
receptor was observed in the untreated hypertensive patients.
This receptor is involved in the activation of T cells and B
cells and raises the possibility of this receptor being a pos-
sible contributor to blood pressure regulation and
inflammation. While small in scope, this hypothesis-gener-
ating study is a basis for further evaluation of the gene
expression profile in both untreated and treated hyperten-
sion. Larger studies of hypertensive individuals may provide
insight into varying pathophysiologic entities that lead to the
final common pathway of elevated blood pressure. More-
over, these studies suggest the possibility that gene
expression may be developed further as a useful tool to assess
average blood pressure over time. Ultimately, clinicians may
be able to utilize gene expression patterns in hypertensive
patients to guide optimal drug selection, to assess blood
pressure control over time, or to predict end-organ outcome.
Diabetes Mellitus
Type 2 diabetes is a well established risk factor for car-
diovascular complications owing to oxidative stress, high
levels of glucose, insulin, and free fatty acids. Given the
significant morbidity and mortality associated with the
cardiovascular complications of type 2 diabetes, develop-
ing biomarkers reflective of underlying pathology and
predictive of disease progression remain an important
objective. PBMCs are exposed to the systemic effects of
type 2 diabetes and were therefore postulated by Takamura
et al. to change their genomic expression in response to the
disease state and reflect the oxidative stress associated with
vascular damage. Takamura et al. (2007) compared sam-
ples from 18 patients with type 2 diabetes and 16 non-
diabetics and found that 48 genes in the c-Jun N-terminal
kinase (JNK)1 pathway were the only ones with consis-
tently elevated gene expression among poorly controlled
diabetics and down-regulated with glycemic control. The
JNK pathway has been implicated in pancreatic b cell
dysfunction as well as in promoting insulin resistance
through its action in the hepatocytes (Kaneto et al. 2004).
This differential expression of the JNK pathway could
provide a better marker of evaluating glucose induced
stress in diabetes as opposed to inflammatory markers like
C-reactive protein (CRP) and tumor necrosis factor (TNF)
a which are not affected by glycemic control. Moreover,
genes associated with mitochondrial oxidative phosphory-
lation (OXPHOS)1 were down-regulated with diabetes and
remained unchanged with glycemic control. Down regu-
lation of genes involved with oxidative phosphorylation
has also been demonstrated in diabetics and pre-diabetics
from gene expression profiling of skeletal muscles (Patti
et al. 2003). These results not only provide additional
validation to past research, but also show that peripheral
blood mononuclear cell gene expression may potentially
serve as an effective, non-invasive marker of diabetes or
pre-diabetes. Additionally, such studies may provide
starting points for researchers to identify novel genes
involved in key glucose regulatory pathways.
Myocardial Infarction (MI)
There are approximately 1.3 million cases of MI each year
with an annual age adjusted rate of 241 cases per 100,000
people (CDC 2005). Although, very sensitive biomarkers
to detect and diagnose MI are used clinically, there is great
need to develop better markers that can predict the risk of
MI. In this direction, Healy et al. used platelet RNA
expression to predict the likelihood of an acute coronary
event (Healy et al. 2006). They profiled mRNA from
platelets of 16 subjects who presented for catheterization
for ST-elevation myocardial infarction (STEMI) and 44
subjects with stable CAD. Their analysis showed that
1 KEGG Pathway
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mRNA found in platelets of individuals having a STEMI
had the strongest upregulation of CD 69 and myeloid
related protein-14 (MRP-14), which are involved in platelet
aggregation and calcium dependent signal transduction
respectively as well as cytoskeletal reorganization and
leukocyte trafficking (Donato 2003). CD69 showed a
2.7-fold higher median expression in patients with STEMI
than with stable CAD. MRP-14 had a 2.2-fold higher
median expression in STEMI as compared to persons with
stable CAD. To correlate MRP-8 and 14 expression with
occurrence of cardiovascular events, Healy et al. then
evaluated MRP-8 and 14 levels in a well-characterized
cohort of postmenopausal women. Using a healthy cohort
of postmenopausal women from the Women’s Health
Study, the researchers looked at the relative risk of a first
cardiovascular event according to increasing quartiles of
baseline MRP-8 and 14 protein levels in serum measured
with ELISA. There was an increase in relative risk of first
cardiovascular event in these apparently healthy women
with increasing quartile of MRP-8 and 14 levels, such that
the women in the highest quartile of MRP-8 and 14 protein
levels had a 4-fold elevation in risk compared to those in
the lowest quartile of MRP-8 and 14 levels. Thus, platelet
expression of MRP-8 and 14 are upregulated prior to acute
MI and chronic elevation of these proteins can predict
vascular events. Secretion of MRP 8 and 14 induces a
thrombogenic, inflammatory response by upregulating
proinflammatory chemokines and ICAMs in endothelial
cells while decreasing the expression of cell junction
proteins (Viemann et al. 2007). Therefore, dissecting the
temporal relationship between vascular endothelial injury
and platelet MRP-8 and 14 expressions will identify if
modulation of MRP-8 or 14 levels can impact outcome in
patients at risk for vascular events. This study suggests that
temporal evaluation of blood RNA profiles from platelets
or other circulating cells may provide predictive and
prognostic information for future cardiovascular events
such as ACS.
Thoracic Aortic Aneurysm (TAA)
Long term hypertension or cystic medial degeneration due
to aging or an underlying genetic defect can lead to the
development of thoracic aortic aneurysm. This poses a
diagnostic challenge because thoracic aortic aneurysm
remains sub-clinical until very late in the progression of
disease. Therefore, early detection of aortic aneurysm is
often critical to a successful treatment outcome. Given the
important role of peripheral blood mononuclear cells in
inflammation and interaction with diseased aortic tissue,
Wang et al. (2007) demonstrated that the gene expression
of PBMCs could identify patients at risk for aortic
aneurysm. Comparing 56 TAA patients and 36 spousal
controls, researchers developed a genomic signature that
they found was specific to aortic aneurysm. Testing the
model on a test set showed an overall accuracy of 78% with
sensitivity and specificity of 81% and 75%, respectively.
Preliminary data also suggested that such a genomic sig-
nature could also distinguish location of aneurysm such as
ascending versus descending aortic aneurysm as well as
familial from sporadic form. These results need further
verification but highlight that genomic signatures are
robust markers of disease and not simply a broad marker of
inflammation and that structural heart disease may also
perturb RNA profiles in blood to yield a non-invasive
means for early detection and or screening of these types of
disorders and the identification of patients who might
benefit from imaging.
Thromboembolic disease
Venous thromboembolism (VTE) is another leading cause
of morbidity and mortality from cardiovascular disease.
There are approximately 250,000 cases of VTE a year and
60% of them are recurrent episodes (Cushman 2007). The
risk of venous thromboembolism is especially pertinent to
patients post surgery or trauma, as well as pregnant
women, or patients with cancer or a hypercoagulable dis-
orders such as antiphospholipid syndrome (APS). Current
diagnostic modalities do not provide a reliable method for
selecting patients with antiphospholipid antibodies
(aPLAs) who are at particularly high risk for adverse out-
comes. Potti et al. showed that PBMC gene expression
profile could both identify a patient with APS as well as
identify patients with APS who were at risk for thrombosis.
The researchers compared two sets of patients: one set
consisted of APS patients with VTE and the other had
patients with VTE without APS. The validation group
consisted of APS patients with VTE versus patients with
asymptomatic aPLAs (Potti et al. 2006). Using a statistical
approach similar to earlier work in breast cancer, (West
et al. 2001; Huang et al. 2003) the researchers found that
their genomic signature was able to pick out patients with
APS among a cohort of VTE patients with 85% accuracy.
Secondly, they could also predict with 100% accuracy APS
patients who would develop thrombosis. This study not
only showed the versatility of PBMC gene expression
profiling but also the robustness of their genomic predic-
tion model. This is a proof of concept that peripheral blood
gene expression may predict recurrent thrombosis; how-
ever, the clinical significance will be a lot more if it can be
extended to arterial thrombosis, such as MI. Even if it
cannot, knowing which patients are at high risk for VTE
will be of clear importance in the anticoagulated
Genomic Med. (2007) 1:105–112 109
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populations with presumptively ‘‘idiopathic’’ VTE/pul-
monary embolism.
Cardiac transplant
Use of PBMC gene expression profiling has made tremen-
dous progress in the area of solid organ transplantation, with
much of the effort focused on developing better tests for
predicting graft rejection (Driscoll et al. 2006; Martı´nez-
Llordella et al. 2007; Starling et al. 2006). Research in
cardiac transplantation, perhaps more than any other organ,
led the way in developing novel blood based test for dis-
tinguishing between quiescence and acute rejection.
CARGO, a landmark three-phase, multicenter study in the
area of cardiac transplantation, showed that PBMC gene
expression profiling could be used to accurately distinguish
between post transplant patients in quiescence versus acute
rejection (Deng et al. 2006). This was achieved by first
identifying a set of 11 genes that best distinguished between
acute rejection and quiescence and then using an indepen-
dent cohort to validate the classifying scheme in a
prospective and blinded manner. Using a scoring system
from 0 to 40, with low scores representing low-risk for graft
rejection, researchers set 20 as a threshold for rejection and
found that this criterion gave an 84% concordance with a
pathologists’ reading of Grade 3A/2R and a 38% concor-
dance with quiescence or Grade 0 biopsy. However, using a
threshold of 30 on patients more than one year post trans-
plant, validation of the test yielded a 99.6% NPV and 6.8%
PPV for acute rejection. This test is commercially available
as AllomapTM (XDx; Brisbane, CA) and costs roughly
$3000 per test. Although it is expensive, cost analysis based
on data from CARGO cohort has shown that this blood
based gene expression profiling test is cheaper than biopsy
and is likely to save as much as $12 million in healthcare
costs annually (Evans et al. 2005). In order for this to be
true, however, the need for biopsy would have to be obvi-
ated and gene expression profiling would have to suffice in
patients considered ‘‘low risk’’ for rejection. Toward that
end, a prospective, multi-center, randomized but non-blin-
ded trial called The Invasive Monitoring Attenuation
Through Gene Expression (IMAGE) has been initiated. The
main hypothesis of the study is that a primarily non-inva-
sive rejection surveillance strategy utilizing GEP testing is
not inferior to endomyocardial biopsy in diagnosing cardiac
allograft dysfunction in rejection and hemodynamic com-
promise (HDC) along with all-cause mortality. Should this
study show favorable results, this will represent a key
example where PBMC gene expression profiling can be
used practically to guide therapeutic decision making in
real-time.
Pulmonary hypertension
Inflammation is purported to play a significant role in the
development of pulmonary hypertension (Dorfmuller et al.
2003). Bull et al. looked at the gene expression profiling of
PBMCs to look for genetic signatures of pulmonary arterial
hypertension (PAH). The gene expression profile of 16
patients with PAH showed 106 differentially expressed
genes that distinguished between controls and PAH
patients with 95–100% accuracy (P \ 0.002) (Bull et al.
2004, 2007). However, within the PAH patients, unsuper-
vised cluster analysis failed to show a genetic signature that
reliably distinguished between secondary pulmonary arte-
rial hypertension and idiopathic pulmonary arterial
hypertension. The small sample size, however, may have
decreased the power to ask this question. Nonetheless,
PBMC gene expression profiling provided a method of
approaching a very difficult problem in a disease where
invasive procedures are both dangerous and costly. More-
over, PBMC gene expression profiling highlighted some
novel genes like herpesvirus entry mediator (HVEM) that
raise hope of continued work in this direction. HVEM is
associated with Human Herpesvirus-8 (HHV-8) infection.
Earlier work by Bull et al. has shown that HHV-8 infection
has been associated with idiopathic PAH (IPAH) and
upregulation of a gene associated with that viral infection
gives more validity to the claim and highlights the versa-
tility of this approach. Given the broad-based nature of
therapies currently available for PAH, identification of
novel genes involved in the pathophysiology of this disease
may enable targeted therapeutic development. Addition-
ally, gene expression determination over time in a given
patient may inform the treating clinician of therapeutic
efficacy or failure.
Summary and conclusions
Studies of gene expression profiling of PMBCs, platelets or
whole blood mRNA highlight the versatility of using gene
expression profiling and the strength of this technique in
identifying genetic signatures associated with a disease,
identification of candidate genes involved in a pathological
process, and in assessing the response to pharmacotherapy.
Beyond its scientific merit, this approach could provide a
more cost effective and less invasive alternative to biopsy
or invasive physiologic measurements. Given this success,
the question remains, how far is this technology from
changing the standard of practice in cardiology clinics?
The answer to that question will depend not only on the
nature of scientific questions one can answer with this
approach, but also on the feasibility of this test in the
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clinical setting and the impact the test will have on clinical
decision making and outcomes. Although the success of a
test like AllomapTM would suggest that genomic technol-
ogy is ready for clinic, but the reality is that the diagnostic
power of the current genomic tools is limited. In order for
gene expression studies to have widespread impact on daily
practice, gene expression tests are going to have to be able
to be specific enough to distinguish between complex
diseases that may have common underlying inflammatory
mechanisms or where multiple diseases may be present
such as in patients with atherosclerosis, diabetes, and
rheumatoid arthritis. The use of whole genome expression
as a technology for detection and prognosis is its infancy.
But the results to date are quite promising in that signatures
can be developed and in some cases reproduced in repli-
cation cohorts. This latter hurdle is an important one that
can be overcome if investigators are motivated and careful
to collect the relevant biological samples associated with
clinical data. The disease tissues for many aspects of car-
diovascular disease are largely inaccessible for study. The
complexity of genomic information in blood based ‘sen-
sors’ of these remote disease processes may be just what
the cardiovascular medicine field needs to propel it in to
the era of genomic and personalized medicine.
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